Korro Bio, Inc.
HealthcareNASDAQ:KRRO · NASDAQ Capital Market
+$1.08 today
Vol 0.32M · Avg 0.16M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-228.0%
avg -27.9%
ROIC
-83.8%
avg -51.8%
ROA
-103.3%
avg -51.7%
Analysis
ROIC is currently the strongest return metric at -83.8% versus its period average of -51.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ram Aiyar | Chief Executive Officer, President, Interim Chief Financial Officer, Principal Financial Officer & Director | $852,656.00 | — | 48 | $74,848.00 | 0.75% |
Loic Vincent | Chief Scientific Officer | $642,518.00 | — | — | $35,000.00 | 0.35% |
Jeffrey Cerio | Senior Vice President, General Counsel & Corporate Secretary | $587,500.00 | — | — | $23,000.00 | 0.23% |
Andrew Fraley | Co-Founder & Advisor | — | — | — | — | — |
Joshua Rosenthal | Co-Founder & Advisor | — | — | — | — | — |
Gaozhong Zhu | SVP of Chemistry, Manufacturing and Controls & Technical Operations | — | — | — | — | — |
Oliver Dolan | Senior Vice President of Finance & Principal Accounting Officer | — | — | 43 | $15,000.00 | 0.15% |
Todd Chappell | Chief Operating Officer | — | — | 53 | $38,000.00 | 0.38% |
Stephanie Engels | Chief People Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
19
$20.72M
Sells
3
$236,569.96
Net Sentiment
+$20.48M
Net buying
Most Active
FORMELA JEAN FRANCOIS
2 transactions
1–10 of 22
Analysis
Insiders reported 19 buys worth $20.72M and 3 sells worth $236,569.96 over the last 12 months. That adds up to net buying of $20.48M. FORMELA JEAN FRANCOIS was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | +11.6% (9yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +11.6% (9yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$814.99M
Alto Neuroscience, Inc.
NYSE:ANRO
$753.47M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
DBV Technologies S.A.
NASDAQ:DBVT
$416.60M
Aura Biosciences, Inc.
NASDAQ:AURA
$411.52M
Silence Therapeutics plc
NASDAQ:SLN
$316.00M
Amarin Corporation plc
NASDAQ:AMRN
$315.21M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$296.96M
Altimmune, Inc.
NASDAQ:ALT
$230.35M
enGene Holdings Inc.
NASDAQ:ENGN
$82.94M
Who manages KRRO?
Korro Bio, Inc. (KRRO) lists 9 active executives. The top listed executive is Andrew Fraley, Co-Founder & Advisor.
Are KRRO insiders buying or selling?
Recent insider activity shows net buying of $54.64M.
Explore More
Continue the stock analysis
Jump to another research area for this company.